DGCR8 Antibody [DyLight 594]
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-30116DL594
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry, Immunoprecipitation
Label
DyLight 594 (Excitation = 593 nm, Emission = 618 nm)
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Antigen maps to a region between residue 400 and 450 of human DiGeorge syndrome critical region gene 8 using the numbering given in entry NP_073557.3 (GeneID 54487).
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for DGCR8 Antibody [DyLight 594]
Application
Recommended Usage
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunoprecipitation
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: DGCR8
Alternate Names
C22orf12, DGCRK6chromosome 22 open reading frame 12, DiGeorge syndrome critical region 8, DiGeorge syndrome critical region gene 8, Gy1, microprocessor complex subunit DGCR8, pasha
Gene Symbol
DGCR8
Additional DGCR8 Products
Product Documents for DGCR8 Antibody [DyLight 594]
Product Specific Notices for DGCR8 Antibody [DyLight 594]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...